Spns2-targeted therapy for multiple sclerosis via S1P transporter inhibition

Overview

This research program targets the S1P transporter Spns2 as a novel therapeutic strategy for multiple sclerosis. Existing MS drugs that modulate S1P receptor signaling carry significant side effects. Preclinical studies in mouse models have demonstrated that genetic deletion of Spns2, either systemically or specifically in lymphatic vessels, effectively blocks lymphocyte trafficking from lymphoid organs, thereby reducing neuroinflammation. Importantly, Spns2 knockout mice were well tolerated under neuroinflammatory conditions, suggesting that Spns2 inhibition may achieve therapeutic benefit while avoiding the adverse effects associated with current S1P receptor-targeting drugs.

Technical specifications

Key features:

• Functional assays developed for large-scale drug screening against Spns2
• Validated cell models for compound testing and characterization
• Established animal models for preclinical validation of candidate therapeutics
• Published foundational data demonstrating proof-of-concept in mouse models
• Targeting mechanism distinct from existing S1P receptor modulators, potentially offering improved safety profile

Technology readiness level

The program is at the preclinical validation stage. Published peer-reviewed results in mouse models provide the scientific foundation for the therapeutic hypothesis. The research team has developed functional assays, cell models, and animal models ready for drug screening and validation studies. Next steps include leveraging research funding for internal drug screening or collaborating with pharmaceutical companies for drug discovery efforts, with the team offering expertise, cell models, and animal models to support these activities.